

News Release

Lonza Publishes Annual Report 2013 and Invitation To the Annual General Meeting 2014

Basel, Switzerland, 20 March 2014 – Lonza today announced that it has published its Annual Report 2013 and its invitation to the Annual General Meeting 2014 that will take place on Wednesday, **16 April 2014**, at **10:00 a.m. CET**.

The Annual Report is as of today available at the company's headquarters. Additional copies can be ordered on the following link, where a pdf of the Annual Report can also be accessed: <http://www.lonza.com/financial-reports>

This year's Annual General Meeting invitation can be accessed on Lonza's website through the following link:

<http://www.lonza.com/investor-information.aspx>

Specific details about each of the proposed candidates and motions can also be found through that link.

The Board of Directors is proposing Barbara Richmond and Juergen Steinemann to be elected as new members of the Board. Peter Wilden will not stand for re-election.

Among the other motions to be introduced are the election of the Chairperson Rolf Soiron, the election of the members of the Nomination and Compensation Committee and the revision of the Articles of Association to align them with the requirements of the Swiss Ordinance Against Excessive Compensation by Public Corporations.

About Lonza

Lonza is one of the world's leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life.

Not only are we a custom manufacturer and developer, Lonza also offers services and products ranging from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from the vitamin B compounds and organic personal care ingredients to

News Release

agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 40 major manufacturing and R&D facilities and approximately 10,000 employees worldwide. The company generated sales of about CHF 3.6 billion in 2013 and is organized into two market-focused segments: Pharma&Biotech and Specialty Ingredients. Lonza's stock is publicly traded on the Swiss and the Singapore stock exchanges. Further information can be found at www.lonza.com.

Lonza Contact Information

Lonza Group Ltd
Head Investor Relations
Dirk Oehlers
Tel +41 61 316 8540
Fax +41 61 316 9540
dirk.oehlers@lonza.com

Lonza Group Ltd
Head Corporate Communications
Dominik Werner
Tel +41 61 316 8798
Fax +41 61 316 9540
dominik.werner@lonza.com

Lonza Group Ltd
Head External Communications
Constance Ward
Tel +41 61 316 8840
Fax +41 61 316 9840
constance.ward@lonza.com